When we think about treating Alzheimer’s disease, we usually think about developing better drugs. But there is another problem that receives much less attention: even if scientists design a promising treatment, how do they get enough of it into the brain?
The brain is protected by the blood–brain barrier (BBB), a tightly regulated boundary between the bloodstream and brain tissue. This barrier is essential for keeping potentially harmful substances away from neurons. Unfortunately, it can also restrict the entry of therapeutic molecules.
Researchers are now investigating a surprisingly physical solution to this biological problem: sound.
More specifically, they are experimenting with focused ultrasound, a technology that can concentrate ultrasound energy on selected areas inside the brain. Combined with microscopic bubbles circulating through the blood, it may allow researchers to temporarily and locally increase the permeability of the blood–brain barrier.
And that could create an entirely new approach to delivering Alzheimer’s treatments.
The idea sounds strange at first. How could ultrasound possibly affect a barrier inside microscopic blood vessels?
The answer involves microbubbles.
Before the ultrasound procedure, tiny gas-filled bubbles can be introduced into the bloodstream. When they reach blood vessels within the area targeted by the ultrasound waves, the bubbles begin to oscillate in response to the acoustic pressure.
These controlled mechanical interactions affect the blood vessel environment and can temporarily increase BBB permeability. Instead of opening the barrier throughout the brain, researchers can target a specific region.
This distinction is important. The blood–brain barrier is there for a reason, so permanently disrupting it would not be desirable. The objective is to create a controlled window and then allow normal barrier function to return.
Some systems combine focused ultrasound with MRI, allowing researchers to plan the target precisely and evaluate whether the intended region has been reached.
From an engineering perspective, this is what makes the technology particularly interesting: sound energy is being used to control biological transport.
Alzheimer’s disease is biologically complicated. Amyloid-β accumulation and abnormal tau proteins are two of its best-known characteristics, but the disease also involves inflammation, synaptic dysfunction, metabolic changes, and progressive neuronal damage.
Several modern Alzheimer’s treatments use monoclonal antibodies designed to interact with amyloid-β. These antibodies are large molecules, however, and only a limited fraction reaches the brain from the bloodstream.
Focused ultrasound could potentially change that equation.
Instead of only asking:
How can we design a better drug?
bioengineers can also ask:
How can we improve the way that drug reaches its target?
One small human study published in The New England Journal of Medicine explored exactly this question. Researchers combined focused-ultrasound blood–brain barrier opening with the anti-amyloid antibody aducanumab.
Only three participants were included, making this a proof-of-concept experiment rather than evidence that the procedure works as an Alzheimer’s treatment. However, the researchers were able to compare brain regions exposed to ultrasound with corresponding regions that were not.
PET imaging showed greater amyloid reduction in the ultrasound-treated areas.
That does not mean focused ultrasound has been shown to improve memory or stop Alzheimer’s. But it provides evidence supporting the idea that engineers may be able to modify how an Alzheimer’s therapy reaches and affects selected areas of the brain.
This is where the story becomes even more interesting.
Scientists are also investigating whether focused ultrasound might produce biological effects independently of drug delivery.
Studies of repeated BBB opening have examined possible changes in amyloid levels and other measures. Results so far are not uniform, and the number of patients in many studies remains small.
Researchers have proposed several mechanisms that might explain these observations. Ultrasound-mediated BBB opening may interact with immune processes in the brain, including the activity of microglia, cells involved in responding to damage and clearing biological material. Scientists are also investigating whether opening the BBB influences how molecules move between brain tissue and the circulation.
These hypotheses are still being investigated. They should not be confused with established clinical benefits.
There is also a separate branch of research called low-intensity focused ultrasound neuromodulation.
Here, the purpose is different. Researchers are not necessarily trying to open the BBB. Instead, they are studying whether carefully targeted acoustic energy can alter activity within neural circuits.
One particularly interesting target is the entorhinal cortex. This region plays an important role in memory and is affected relatively early during Alzheimer’s disease. Researchers are studying whether targeting it with low-intensity focused ultrasound can influence neural activity, connectivity, or memory-related functions.
So the same broad technology—focused ultrasound—is being investigated from two very different directions:
Can we use it to improve drug delivery?
and
Can we use it to influence the brain itself?
Focused ultrasound might sound like a purely medical technology, but making it work requires several areas of engineering at once.
First, there is the problem of the skull.
Bone changes the way ultrasound waves travel. If researchers want acoustic energy to converge on a small target deep inside the brain, they need to account for how the skull absorbs and distorts those waves.
Modern approaches can therefore involve medical imaging, computational treatment planning, multiple ultrasound elements, and navigation systems.
Then there is the problem of the microbubbles.
Their behavior must be carefully controlled. Under ultrasound exposure, microbubbles can produce acoustic signals that researchers detect and analyze. This phenomenon is associated with cavitation, and monitoring it can provide information about what is occurring during the procedure.
A recent pilot study demonstrated why this could become important. Researchers tested a portable, neuronavigation-guided focused-ultrasound system in six people with mild-to-moderate Alzheimer’s disease. They were able to achieve BBB opening in five participants and simultaneously monitor acoustic activity during treatment.
The relationship between the measured cavitation activity and the amount of BBB opening raises an exciting engineering possibility.
Future devices might not simply deliver a fixed ultrasound exposure.
They could potentially listen, calculate, and adapt.
Imagine a system that sends ultrasound toward a target, measures the acoustic response of the microbubbles, determines whether the desired biological effect is being produced, and adjusts its output accordingly.
That would turn focused-ultrasound treatment into something resembling a closed-loop control system, where biological feedback influences what the device does next.
Many experimental focused-ultrasound procedures have relied on sophisticated MRI-guided equipment. MRI provides extremely useful anatomical information, but relying on a large MRI system also makes treatment more complicated and expensive.
That is why research into portable and neuronavigation-based systems is particularly important.
If engineers can eventually achieve accurate targeting and reliable real-time monitoring without requiring an MRI scanner throughout the entire procedure, focused-ultrasound technology could potentially become easier to implement in clinical environments.
However, portability creates its own engineering challenges. A smaller system still has to answer the same fundamental questions:
Where exactly is the acoustic energy going?
What are the microbubbles doing?
How much BBB opening has occurred?
And when should the system stop?
Solving those questions requires combining acoustics, neuroscience, medical imaging, signal processing, computational modeling, and control engineering.
This is where we need to be careful.
Successful BBB opening is not the same thing as successful Alzheimer’s treatment.
A device can successfully target a region. MRI can confirm that the BBB was temporarily opened. PET imaging can detect a biological change. But ultimately, an Alzheimer’s therapy has to demonstrate something much more important: meaningful benefit for patients.
A 2026 systematic review of human clinical research on focused-ultrasound BBB opening found encouraging evidence regarding the feasibility and short-term safety of the approach. At the same time, the studies differed considerably in their methods, targeted brain regions, ultrasound parameters, and outcome measurements.
Evidence for cognitive improvement remains uncertain.
This means focused ultrasound should currently be viewed as an experimental technology being investigated for Alzheimer’s, not as an established treatment.
Researchers still need to determine which patients might benefit, which brain regions should be targeted, how often treatment should occur, how ultrasound should be combined with drugs, and whether repeated BBB opening remains safe over longer periods.
Most importantly, larger controlled clinical trials will have to determine whether changes visible on brain imaging translate into preserved memory, cognition, or everyday functioning.
Focused ultrasound highlights something I find fascinating about bioengineering: treating disease does not always begin with inventing a new molecule.
Sometimes, the challenge lies in delivery.
Scientists may develop an antibody capable of recognizing a disease-related protein, but that does not automatically mean the antibody can efficiently reach its target inside the brain. Biology creates boundaries, and engineering can sometimes provide ways to navigate them.
Focused ultrasound attempts to do exactly that.
Using sound waves, microbubbles, imaging, computational targeting, and real-time acoustic monitoring, researchers are trying to control access to one of the most protected environments in the human body.
Whether this technology will ultimately improve the lives of people with Alzheimer’s remains an open question.
But the concept itself represents an exciting shift in perspective.
Instead of only engineering what we give to the brain, perhaps we can also engineer how we reach it.
Rezai, A.R. et al. (2024). Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease. The New England Journal of Medicine.
Niknam, N. et al. (2026). Ultrasound-induced blood-brain barrier opening in Alzheimer's disease: a systematic review of clinical studies. Aging Clinical and Experimental Research.
ClinicalTrials.gov, NCT05417555. Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease.
ClinicalTrials.gov, NCT05469009. Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody Therapy.